Last updated: August 15, 2026
BUNAVAIL is a buprenorphine/naloxone buccal film that uses BioErodible MucoAdhesive technology to deliver an opioid-dependence treatment through the buccal mucosa. Its commercial differentiation depends less on the active ingredients than on excipient selection, film adhesion, rapid hydration, taste control, dose uniformity, and resistance to diversion. The principal opportunity for excipient suppliers and generic developers is to reproduce or improve the film’s performance without infringing formulation, process, or method-of-use patents.
What is BUNAVAIL and how does its formulation work?
BUNAVAIL is an FDA-approved buprenorphine and naloxone buccal film marketed under NDA 207975. It contains a 4:1 ratio of buprenorphine to naloxone by dose, with labeled strengths of 2.1 mg/0.3 mg, 4.2 mg/0.7 mg, and 6.3 mg/1 mg.[1]
The film is placed against the inside of the cheek. Saliva hydrates the dosage form, allowing the mucoadhesive matrix to adhere to the buccal mucosa and release the active ingredients. The route is intended to reduce swallowing and gastrointestinal exposure compared with a conventional sublingual tablet.
BUNAVAIL’s formulation strategy addresses five technical requirements:
- High drug loading in a thin film.
- Adhesion to wet mucosal tissue.
- Rapid onset of hydration and drug release.
- Acceptable taste and mouthfeel.
- Dose uniformity across small, individually packaged films.
The dosage form uses BioErodible MucoAdhesive, or BEMA, technology developed by BioDelivery Sciences International. The platform is based on a dissolving or eroding polymer film that holds drug at the mucosal surface.[2]
What excipients are used in BUNAVAIL?
Public FDA labeling identifies a multi-component excipient system that supports film formation, mucoadhesion, buffering, flavor, sweetening, color, and physical stability.[1]
BUNAVAIL inactive ingredients
| Excipient or excipient class |
Primary formulation function |
| Hydroxypropyl methylcellulose |
Film formation, viscosity control, matrix strength |
| Hydroxypropyl cellulose |
Film structure, wetting, release control |
| Polycarbophil |
Mucoadhesion and residence time |
| Sodium alginate |
Film-forming and mucoadhesive contribution |
| Sodium benzoate |
Preservative and formulation stabilizer |
| Citric acid |
pH adjustment and taste modification |
| Sodium citrate |
Buffering capacity |
| Sweetener system |
Reduction of buprenorphine and naloxone bitterness |
| Flavor system |
Patient acceptability |
| Titanium dioxide and approved colorants |
Appearance and product identification |
The exact commercial value of each excipient depends on its functional contribution. A generic developer cannot treat the ingredients as interchangeable raw materials. Polymer grade, substitution level, molecular weight, particle size, hydration rate, and supplier manufacturing process can change adhesion, dissolution, tensile strength, and content uniformity.
Which excipients create the strongest commercial opportunities?
The largest opportunities are in mucoadhesive polymers, rapidly dissolving film-formers, taste-masking systems, and excipients engineered for opioid products.
Mucoadhesive polymers
Polycarbophil and related crosslinked polyacrylic-acid materials are central to residence time. A supplier that can provide pharmaceutical-grade polymer with narrow viscosity and swelling specifications may compete on:
- Adhesion strength
- Residence time
- Reduced irritation
- Lower variability between lots
- Faster release after adhesion
- Improved stability under high humidity
Potential substitutes include carbomer grades, thiolated polymers, modified cellulose systems, alginates, chitosan derivatives, and polymer blends. Each substitute raises regulatory and patent risks because a change in polymer chemistry can affect dissolution, bioequivalence, and the claimed formulation architecture.
Film-forming polymers
Hydroxypropyl methylcellulose and hydroxypropyl cellulose provide mechanical integrity and processing control. Film suppliers can create value by optimizing:
- Drying temperature
- Film thickness
- Polymer molecular weight
- Plasticizer concentration
- Web-coating behavior
- Curl and peel resistance
- Moisture transmission
A thinner film can improve patient comfort but may reduce drug-loading capacity. A higher polymer concentration can improve mechanical strength but delay erosion and drug release.
Taste-masking excipients
Buprenorphine and naloxone have challenging taste profiles. Taste masking is commercially important because opioid-dependence treatment often requires repeated daily administration. Opportunities include:
- High-intensity sweeteners
- Flavor-modulation systems
- Ion-exchange resins
- Cyclodextrins
- Lipid or polymeric microencapsulation
- pH-mediated reduction of bitterness
- Functional coatings that dissolve after adhesion
Taste-masking technology must preserve rapid buccal release. A system that improves taste by reducing dissolution at the mucosal surface may compromise bioavailability.
Buffer systems
Citric acid and sodium citrate control microenvironmental pH. A buffer system can affect:
- Buprenorphine ionization
- Naloxone ionization
- Mucosal permeability
- Film stability
- Taste
- Local irritation
- Release rate
Alternative buffering systems may create a product-differentiation opportunity, but they can also change pharmacokinetics enough to trigger a more extensive FDA bioequivalence program.
What formulation patents protect BUNAVAIL?
BUNAVAIL’s intellectual-property position is associated with BEMA-based buprenorphine/naloxone films, manufacturing methods, and formulation characteristics. Public patent records include U.S. Patent No. 8,808,737, titled “Buprenorphine and naloxone buccal film compositions,” assigned to BioDelivery Sciences International.[3]
A related continuation patent family includes U.S. Patent No. 9,629,965.[4] The family generally targets combinations of:
- Buprenorphine and naloxone in a buccal film
- Mucoadhesive polymer matrices
- Drug loading and film architecture
- Buccal administration
- Dosage-form performance
- Manufacturing or coating processes
Patent expiration for these family members is generally associated with the underlying priority and patent-term calculation in the late 2020s. Regulatory patent listings and current legal status should be assessed at the individual patent and claim level because terminal disclaimers, patent-term adjustment, pediatric extensions, and post-grant proceedings can change effective exclusivity.
The commercial implication is direct: a generic competitor may avoid literal infringement by changing the polymer blend, film architecture, manufacturing sequence, or release profile. That approach can increase development risk if the resulting product no longer meets the reference product’s bioequivalence requirements.
What is the Orange Book status of BUNAVAIL?
BUNAVAIL is listed in FDA drug databases as an approved buprenorphine/naloxone buccal film product under NDA 207975.[1,5] The Orange Book is the relevant source for listed patents and regulatory exclusivity associated with approved strengths.
The key regulatory issues are:
- Whether the NDA remains active or has been identified as discontinued.
- Whether listed patents remain in the current Orange Book.
- Whether any patent has been delisted or removed.
- Whether a generic applicant can submit an ANDA with a Paragraph IV certification.
- Whether FDA recognizes any remaining regulatory exclusivity.
For an ANDA applicant, a Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. A successful challenge could support an earlier generic launch. A Paragraph III certification would defer approval until patent expiry.
BUNAVAIL is a small-molecule combination product, not a biologic. Biosimilar litigation and the Biologics Price Competition and Innovation Act do not apply. Generic competition proceeds through the ANDA pathway.
When does BUNAVAIL lose exclusivity?
The practical loss of exclusivity depends on three separate dates:
| Exclusivity element |
Relevance to BUNAVAIL |
| FDA regulatory exclusivity |
Controls when certain ANDA submissions or approvals may proceed |
| Listed patent expiry |
Controls the timing of non-infringing or successfully challenged generic entry |
| Market and commercial status |
Determines whether a generic launch can generate meaningful sales |
BUNAVAIL was approved in 2014. Any five-year new chemical entity exclusivity associated with the NDA would have expired before the current patent horizon. The remaining barrier has therefore been primarily patent-based and commercial rather than NCE exclusivity.
A generic entrant would likely evaluate three launch scenarios:
- At-risk launch: Entry before all relevant patents expire after a Paragraph IV challenge.
- First lawful launch: Entry after patent expiry or a settlement date.
- Delayed or limited launch: Entry after resolving litigation but with restricted manufacturing capacity or a narrow product portfolio.
Which companies are positioned to challenge BUNAVAIL?
The most credible challengers are generic manufacturers with existing buprenorphine/naloxone products, thin-film manufacturing capacity, or opioid-dependence treatment portfolios. Potential participants include large ANDA developers and specialized film-dose manufacturers.
Competitive pressure comes from three directions:
- Sublingual buprenorphine/naloxone tablets
- Generic sublingual films
- Long-acting injectable buprenorphine products
A BUNAVAIL generic must compete against the reference film and against lower-cost dosage forms. It also must satisfy controlled-substance manufacturing, diversion-control, serialization, packaging, and supply-chain requirements.
Public information does not establish a complete current list of active Paragraph IV challengers or settlement agreements for every BUNAVAIL patent. Patent litigation databases, FDA Paragraph IV notices, and Orange Book updates should be reviewed together because a litigation filing does not establish commercial launch timing.
How strong is the BUNAVAIL patent estate?
The estate is strongest where claims combine the active ingredients with the BEMA film platform and defined performance characteristics. It is weaker where a competitor can use a different polymer system while meeting the same clinical and bioequivalence requirements.
Strength factors
- Early-mover position in buprenorphine/naloxone buccal film.
- Platform-specific film and mucosal-delivery claims.
- Potential protection for manufacturing and film composition.
- Difficulty of changing excipients without affecting bioequivalence.
Weakness factors
- The active ingredients are established and widely available.
- Sublingual and buccal opioid products have substantial prior art.
- Generic developers can pursue alternative polymer systems.
- Patent expiry is approaching compared with newer long-acting products.
- Commercial demand is exposed to lower-cost tablets and injectable therapies.
The patent estate is therefore more valuable as a formulation and manufacturing barrier than as a barrier to the active ingredients.
What manufacturing and excipient barriers affect generic entry?
Manufacturing is a material barrier. A developer must control solution or suspension uniformity before coating, web tension, drying, die-cutting, packaging, and moisture protection.
Critical quality attributes include:
- Assay and content uniformity
- Film thickness
- Tensile strength
- Adhesion
- Disintegration or erosion time
- Dissolution profile
- Residual moisture
- Water activity
- Appearance
- Package integrity
The highest-risk process step is usually drug distribution across the film. Buprenorphine and naloxone must remain uniformly distributed despite differences in solubility, particle behavior, and interaction with the polymer matrix.
Excipient suppliers can capture value by offering qualified grades with documented control over viscosity, hydration, residual solvents, microbial quality, and elemental impurities. Dual sourcing is difficult when a polymer grade changes film performance. This creates switching costs and can support long-term supply agreements.
What licensing deals and commercial opportunities exist?
The most attractive licensing targets are platform technologies that improve buccal delivery without requiring a new active ingredient. Relevant assets include:
- Low-dose opioid films
- Non-opioid addiction-treatment films
- Pediatric or geriatric buccal films
- Taste-masked controlled substances
- Heat- and humidity-stable film packaging
- Continuous coating and high-throughput converting
- Abuse-deterrent mucoadhesive systems
Potential counterparties include excipient manufacturers, contract development and manufacturing organizations, specialty pharmaceutical companies, and generic manufacturers seeking a differentiated film platform.
A licensing package is strongest when it combines formulation know-how, analytical methods, scale-up data, and freedom-to-operate analysis. A single polymer patent is less valuable than a validated platform with reproducible commercial manufacturing.
How does BUNAVAIL compare with competing buprenorphine products?
| Product category |
Administration |
Main commercial advantage |
Main limitation |
| BUNAVAIL |
Buccal film |
Thin film, mucoadhesion, reduced tablet burden |
Formulation complexity and patent exposure |
| Suboxone film |
Sublingual/buccal film |
Established brand and broad prescriber familiarity |
Mature competition |
| Generic buprenorphine/naloxone tablets |
Sublingual tablet |
Low cost |
Lower differentiation and possible patient preference issues |
| Sublocade |
Long-acting injection |
Monthly treatment and reduced daily dosing |
Injection administration and higher treatment complexity |
| Brixadi |
Long-acting injection |
Weekly or monthly dosing options |
Requires healthcare-provider administration |
BUNAVAIL’s excipient advantage is most relevant where patients value a small, discreet, rapidly dissolving film. Its commercial weakness is that excipient sophistication does not by itself prevent substitution by lower-cost tablets or long-acting injectable products.
Key Takeaways
- BUNAVAIL is a buprenorphine/naloxone buccal film based on BEMA technology.
- Its core excipient strategy uses cellulose film-formers, polycarbophil and alginate-type mucoadhesive materials, buffers, sweeteners, flavors, and colorants.
- The strongest commercial opportunities are in mucoadhesive polymers, taste masking, film processing, and moisture-protective packaging.
- U.S. Patent Nos. 8,808,737 and 9,629,965 are central public members of the BUNAVAIL formulation patent family.
- Generic entry risk is driven by patent expiry, alternative polymer architectures, ANDA bioequivalence, and the availability of competing tablets and injections.
- BUNAVAIL has no biosimilar pathway risk because it is a small-molecule drug.
- Excipient suppliers with narrow-specification polymer grades and validated film-processing support have the clearest licensing and supply opportunities.
FAQs
Can a generic BUNAVAIL use different excipients?
Yes. An ANDA applicant can use different inactive ingredients if the product meets applicable FDA requirements, demonstrates bioequivalence, and does not infringe enforceable patents.
Which excipient is most important for BUNAVAIL adhesion?
Polycarbophil is a key mucoadhesive component, but adhesion depends on the entire polymer matrix, hydration profile, film thickness, and manufacturing process.
Is BUNAVAIL an abuse-deterrent opioid product?
BUNAVAIL is designed for buccal administration and includes naloxone, which is intended to reduce the attractiveness of parenteral misuse. The product should not automatically be classified as abuse-deterrent under every FDA abuse-deterrence category.
Can BUNAVAIL technology be used for non-opioid drugs?
Yes. Mucoadhesive buccal films can be adapted to other low-dose drugs, particularly compounds with poor gastrointestinal absorption, unpleasant taste, or a need for rapid transmucosal delivery.
What is the main barrier to commercializing an alternative BUNAVAIL film?
The main barrier is simultaneous control of content uniformity, adhesion, dissolution, taste, packaging stability, and bioequivalence while avoiding the relevant formulation and process claims.
References
- U.S. Food and Drug Administration. (2014). BUNAVAIL (buprenorphine and naloxone) buccal film prescribing information.
- BioDelivery Sciences International, Inc. (2014). BUNAVAIL buccal film: Product and technology information.
- U.S. Patent No. 8,808,737. (2014). Buprenorphine and naloxone buccal film compositions. U.S. Patent and Trademark Office.
- U.S. Patent No. 9,629,965. (2017). Buprenorphine and naloxone dosage forms and methods. U.S. Patent and Trademark Office.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
